Merck Tbk PT
IDX:MERK
Merck Tbk PT
IDX:MERK
Price:
3 170
IDR
-0.31%
Market Closed
Market Cap:
Rp1.4T
Relative Value
The Relative Value of one
MERK
stock under the Base Case scenario is
4 578.65
IDR.
Compared to the current market price of 3 170 IDR,
Merck Tbk PT
is
Undervalued by 31%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MERK
Relative Value
Base Case
4 578.65
IDR
Undervaluation 31%
Multiples Across Competitors
MERK Competitors Multiples
Merck Tbk PT Competitors
Merck Tbk PT Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ID |
|
Merck Tbk PT
IDX:MERK
|
1.4T IDR | 1.3 | 8 | 5.6 | 5.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
994.4B USD | 15.3 | 48.2 | 32.5 | 34.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282.2B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.1B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.7B GBP | 5.1 | 31.7 | 15.1 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.1B USD | 4.5 | 16 | 10 | 11.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.6 | 13.8 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.3B USD | 2.6 | 17.6 | 6.9 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
